The Science and Art of De-risking Cancer Drug Development

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/7a/89/d2/7a89d2eb-58c2-8887-e394-e727c76dc72f/mza_5501671720659720569.jpg/600x600bb.jpg

Talking Precision Medicine

Genialis

51 episodes

1 week ago

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Life Sciences

Science

RSS

All content for Talking Precision Medicine is the property of Genialis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/1109085/1109085-1591869612639-da4fed0a60a7.jpg

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

Talking Precision Medicine

31 minutes 27 seconds

1 year ago

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.

Episode 35 links: